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Epidemiology of Hepatocellular Carcinoma
in Florida – Part I: A Statewide Report
Angel E. Alsina, MD, Aryan Beharry, Narrad Beharry, PhD, MSPH,
Nyingi Kemmer, MD, Edson Franco, MD, Haydy Rojas, RN, Guy W. Neff, MD
ABSTRACT
The increasing incidence of hepatocellular carcinoma (HCC) has become a burgeoning public health problem. The effect has
been most notable at liver transplant centers. Traditional reports of liver cancer include many non-HCC variants. This study
aims at determining the incidence of HCC in the state of Florida, utilizing data from Florida Cancer Data Systems. This
study pertains exclusively to HCC. Of 2,296,794 cancer cases, 4,447 HCC and variants were identified (68.7%). Incidence
rates were as follows. The incidence of HCC in the state of Florida was 6.1 cases /100,000 population/year; Male:
9.6/100,000 population/year vs. Female: 2.7; Whites: 6.5/100,000 population/year vs. Blacks: 5.3; Hispanics: 4.6/100,000
population/year vs. Non-Hispanics: 6.5. Limitations of the study included lack of etiology of liver disease, treatments and
survival. The classification of tumors and under-reporting in the database are also concerns. The study elaborates on guidelines for screening and diagnosis of HCC. The incidence of HCC in Florida in this study was three times higher than previous
reports from 2 decades ago. This is the most updated study reporting the incidence of HCC in Florida, although data was 5
years old. The incidence of this cancer is expected to continue to increase over the next decade. The study is a preamble to socioeconomic and county studies currently being performed at this liver transplant center.
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Background
Hepatocellular carcinoma (HCC), a primary malignancy of the liver and one of the most common
malignancies worldwide accounts for more than 1
million deaths annually. The increasing incidence of
HCC has started to become a burgeoning public
health problem. Recent publications during the past
40 years have noted a significant rise in the incidence of HCC within the United States (Altekruse,
McGlynn, & Reichman, 2009).
The geographic distribution of HCC has been
linked to a multitude of risk factors: Hepatitis B virus and Hepatitis C virus being the two most implicated factors. It has been shown that the distribution
of HCC is closely related to the incidence of hepatitis
B/C virus infection. Therefore, not surprisingly,
because the high rates of horizontal transmission of
hepatitis B, the highest incidences of HCC are found
in Southeast Asia and Africa (greater than 10 to 20
per 100,000), whilst the lowest incidence is found in
Australia, North America and Europe (1-3 per
100,000).
HCC has been demonstrated to be the third
leading cause of cancer mortality worldwide (Altekruse et al., 2009). It has also been shown that approximately 90% of primary liver carcinomas within
the United States are HCC, while the remaining 10
percent are cholangiocarcinomas. It has been established throughout literature that a large percent of
HCC is significantly associated with hepatitis viral
infection, while other factors include alcohol use,
smoking, genetic metabolic disease, cirrhosis, envi-
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ronmental exposure, chronic infections and family
history of liver cancer.
Over the past 20 years, the age adjusted incidence of HCC has nearly tripled in the United
States, ignited by the unforeseen incidence of chronic Hepatitis C and Hepatitis B. At present there are 4
million US citizens afflicted with chronic Hepatitis C
and 1.2 million afflicted with chronic hepatitis B.
Like the rest of the U.S., the incidence of liver cancer
has increased significantly within the state of Florida. Whether the increased incidence is related to
immigration, increased screening, increased rate of
hepatitis B or hepatitis C infection, cirrhosis, obesity/diabetes mellitus or a combination has yet to be
determined. HCC is the fastest growing cause of
cancer-related deaths in the U.S. (National Cancer
Institute [NCI], 2006) and has the highest mortality
in the obese population (Calle, Rodriguez, Thun &
Walker-Thurmond 2003).
Previous reports of liver cancer in Florida come
from two recent sources. In 2001, from the Department of Epidemiology and Public Health, the overall
incidence between 1985 and 1995 was 2.01/100,000
population; 3.29/100,000 in Hispanics; 1.82/100,000
in white males; 3.86/100,000 in Black males;
1.23/100,000 and 1.18/100,000 in Hispanic and
Black females, respectively; and 0.6/100,000 in
White females (Shea, Fleming, Wilkinson, WohlerTorres, & McKinnon, 2001). The second study was
from the Bureau of Epidemiology, Florida Department of Health (DOH) (Florida Department of
Health: Bureau of Epidemiology [DOHBOE],

18
1

Florida Public Health Review, Vol. 9 [2012], Art. 3

2005). In this 2005 study, 1,127 new cases of liver
cancer were diagnosed that year. The age adjusted
incidence was 5.1 per 100,000 population. This rate
was below the national incident rate of 6.8% and 2.5
times higher than the incident rate in 1981. Mortality was 3.9 per 100,000 population (below national
rate of 5.3), and 45% higher than in 1981, with 890
Floridians dying of liver cancer in 2005.
This study aims at determining the incidence of
HCC in the state of Florida, utilizing data from
FCDS which contains all liver cancer types. Different from the 2005 DOH report on Epidemiology of
Liver Cancer, this study pertains exclusively to hepatocellular carcinoma and its variants. Therefore,
our study has the most updated incidence data and
characteristics of HCC in Florida. It is unique in this
respect. The study is a preamble to socioeconomic
studies of HCC and transplant center studies on
HCC performed by our liver transplant center.
Methods
Available data for liver cancer in Florida comes
primarily from The Florida Cancer Data System
(FCDS), Florida’s statewide population based cancer
registry (DOHBOE, 2005). The system has collected
cancer incidence data since 1981. The last report on
liver cancer came in 2005, collected by FCDS under
contract by the DOH. The data does not include
cancers diagnosed before a person became a Florida
resident. The FCDS has achieved the highest standard and received “Gold Certification” for quality,
completeness, and timeliness for the data collected
for each year from 2000 to 2005.
The FCDS implemented case-finding strategies
to ensure a complete database. Mortality follow-back
was implemented to identify unreported cancer cases
from death data. Death certificates were checked
annually. A process implemented by the FCDS uses
hospital discharge data from the Florida Agency of
Health Care Administration (AHCA) to identify
missed cases and compared to the FCDS database.
Cancer cases that are identified in the AHCA data
and that are missing in the FCDS database are “followed back” to the hospital to obtain complete reports. This procedure has also been employed to
ascertain new cancer cases from ambulatory surgical
centers.
The STAT CD from FCDS, containing data for
the years 1983 to 2010, with a total of 2,296,794
cancer cases was decoded using the Data Acquisition
Manual, 2009. The site code 2627 actually included
both liver (HCC) and intrahepatic bile duct cancer,
or cholangiocarcinomas (CCA) (ICCD-9 155, 155.2,
and 155.1; ICD-03 is C22 and C22.1), and other liver
tumors. We included only data for the 2004-2008
period, the most recent time period, as reported in
FCDS and our period of interest. All age ranges
were included. Only HCC cases were selected for
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analysis. Incident cases for each county were reported per 100,000 population per year. Population
data were obtained from the U.S. Census Report
(U.S. Census Bureau [USCB]) and from the FCDS
2010 Hispanic Report (Fleming 2001, 2010; Hernandez, 2010; Lee, 2010; MacKinnon, 2001, 2010).
The Stat CD data was transferred to an Excel program and files compressed using statistical program
J zip version 1.3. Fisher’s exact 2-tailed tests were
utilized, with p values less than 0.05 deemed significant. Permission from FCDS to conduct the research
and approval from the University of South Florida
Institutional Review Board was obtained.
The following variables were analyzed: age,
ethnicity, race, tumor grade, marital status, diagnostic methods, morphology (histologic type), sex, stage
(local, regional, distant), insurance payer, and county
of origin at time of tumor diagnosis. Since 59% of
cases had unknown grade, this variable was not further analyzed. Non-Hispanics likely included Blacks
and Asians, making ethnicity composition questionable. This is explained in the 2010 FCDS Hispanic
report (Hernandez, et al. 2010), as follows: [“Hispanics” include both Blacks and Whites in part because this follows the patterns of Hispanic raceethnic self-identification (i.e., Black Hispanics often
identify as “Hispanics” rather than “Black”), and because the numbers of identified Black Hispanics in
the FCDS database are quite small. These analyses
do not include non-Hispanic Blacks who are a mixture of African Americans and Blacks from other
countries (particularly the Caribbean)]. Stepwise
case-finding of HCC cases is described below.
Results
Originally, the study began with 2,296,794 cancer cases. Of these cases, 6,474 were classified as
liver tumors. Among the liver tumors, there were
2,025 (31.3%) non-HCC and 4,447 (68.7 %) HCC.
The non-HCC tumors included adenomas, benign
tumors, cholangiocarcinomas, vascular tumors, and
many other variants. Cholangiocarcinomas accounted for 9.6% of all tumors. HCC and variants
are depicted in Table 1. Only the tumors in Table 1
were included in the incidence study and comprised
all HCC cases. Incidence rates were as follows. The
incidence of HCC in the state of Florida was 6.1 cases /100,000 population/year; Male: 9.6/100,000
population/year vs. Female: 2.7/100,000 population/year; Whites: 6.5/100,000 population/year vs.
Blacks: 5.3/100,000 population/year; Hispanics:
4.6/100,000 population/year vs. Non-Hispanics:
6.5/100,000 population/year.
Table 2 displays percentages of all study variables. Males, Whites and Non-Hispanics were the
predominated variables. Uninsured HCC patients
comprised 7.9 % of all HCC cases. Tumor grade was
not recorded in 59% of HCC cases. Only 43% of the
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Table 1. HCC Cases 2004-2008
__________________________________________
No.
% HCC
Mixed HCC/CCA
70
1.5
Clear cell
29
0.6
Fibrolamellar
16
0.3
HCC NOS
4320
97
Pleomorphic
1
< 0.001
Spindle cell
13
0.2
__________________________________________
Total
4,447
NOS = Not otherwise specified
cases presented with local disease. HCC cases peaked
at age 50-59 (1,435 cases, or 358/yr) (Table3). No
difference in staging was observed among different
age groups. However, there were more uninsured
cases in the 30-59 age compared to 60-89 (16% vs.
2.6%, p=.0001).
A detailed county incidence study has been conducted and will be reported separately. The frequency of counties at incidence range of 0-4/100,000
population was 20%; at 5-6/100,000 was 44%; at 67/100,000 was 24% and at 7-9/100,000 was 22%.
Union County was an outlier, with 33 HCC cases for
an incidence of 56.8/100,000 population. It also contained the largest proportion of Blacks as percentage
of total HCC cases (51%).
Discussion
Our study updates the incidence of HCC in
Florida for the period between 2004 and 2008. The
incidence was 6.1 cases/100,000 population. Although data used for this study is almost 5 years old,
the incidence of HCC in Florida has continued to
increase. This is based on previous state reports
which estimated the incidence at 5.1/100,000 population, a study that also included bile duct cancers
(DOHBOE, 2005). As we expected, the incidence
was similar to previous national reports on HCC
(Altekruse et al., 2009; El-Serag et al., 2003). Compared to a 1985-1995 incident HCC report, the incidence tripled during the time period we examined
(DOHBOE, 2005). Whites and Non-Hispanics comprised the majority of HCC cases. The
incidence was lower in Blacks vs. Non-Blacks and
lower in Hispanics vs. Non-Hispanics. This finding
is contrary to what would be expected, based on
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Table 2. Study Variables
___________________________________________
Percent of HCC Cases
χ2
trend
Race

Black
White

14.1
85.9

Ethnicity
Hispanic
Non-Hispanic

16.1
83.9

Payer

Grade

Medicaid
10.2
Medicare
46.2
Not Insured
7.9
Private
30.4
Tricare, Military, VA,
Indian/Public Health
Service
2.3
Unknown
3.0
Well diff.
Mod
Poor
Undiff
Unknown

Diagnostic Method
Pos. Cytology
Pos Histology
Pos Micros conf
Radiography
Unknown
Stage

Local
Regional
Distant
Unknown

18.0
14.4
7.8
0.7
59.0
4.6
82.5
0.2
12.0
0.7
43.0
21.1
14.0
21.3

p < .0001

p < .0001

p < .0001

p < .0001

p < .0001

p < .0001

Sex

p < .0001
Female
22.6
Male
77.4
__________________________________________
previous data (Altekruse et al., 2009; El-Serag et al.,
2003). The FCDS database has limitations in the
racial and ethnicity composition and we recognize
this as a limitation in our study. Asians, who have a
known
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Table 3. Age Distribution HCC
__________________________________________
Decade

HCC Percent

<10
0.04
10-19
0.2
20-29
0.5
30-39
1.3
40-49
8.3
50-59
32.3
60-69
22.0
70-79
22.7
80-89
12.5
__________________________________________
high incidence of HCC, are not categorized. Inclusion of liver cancers other than HCC in previous
Florida reports may account for these differences as
well. Characteristics of the Hispanic population in
Florida and corresponding HCC incidence are the
subjects of our current research. As expected, males
predominated 3.5 to 1. Many tumors have androgen
receptors (Nagasue et al., 2005). The preponderance
of risk factors for HCC in males is well known.
HCC were the tumors of interest, based on rising incidence. These tumors have accounted for as
many as 20-30% of liver transplant indications at
some centers, including ours. These are also cancers
that arise from risk factors that are well known and
we can control. In contrast, cholangiocarcinomas,
which in this database comprised 9.6% of all tumors
similar to previous reports of 8% (Goodman, 2007),
have poorly defined risk factors and occur frequently
in absence of cirrhosis. There is some concern in the
data about the histologic classification of the tumors
according to well established nomenclature, such as
the WHO Histological Classification (Enjoji, 2008).
Epithelial tumors comprise a large segment of liver
tumors. There are benign variants, which include
hepatocellular adenomas, focal nodular hyperplasia,
intrahepatic bile duct adenomas and cystadenomas,
and biliary papillomatosis. Several malignant variants are also included within the epithelial tumors,
including HCC, intrahepatic Cholangiocarcinoma,
bile
duct
Cystadenocarcinoma,
mixed
HCC/Cholangiocarcinoma, Hepatoblastomas, and
other undifferentiated tumors. There were 202 epithelial tumors in the database (3.1% of all total tumors, or 10% of non-HCC tumors), that were unclassified as above, some of which were malignant
per degree of grade reported. Some of these may
have been HCC, possibly underscoring the true incidence of HCC.
In this report, 14% of patients with HCC were
reported as having distant metastases and in 21% of
the cases the staging was unknown. This is certainly
concerning. Our liver transplant center, which spe-

Florida Public Health Review, 2012; 9, 18-23.

http://health.usf.edu/publichealth/fphr/index.htm

https://digitalcommons.unf.edu/fphr/vol9/iss1/3

cializes in HCC, has concentrated on education related to screening for liver cancer in patients that
are at risk, based on the presence of chronic liver
disease, cirrhosis, a positive family history and infectious hepatitis, particularly chronic hepatitis B and
C, among other risk factors. This information has to
be spread through the oncology and gastroenterology medical communities, but most importantly,
through the primary care and internal medicine specialties. Guidelines for the screening, diagnosis and
treatment of hepatocellular carcinoma came from
published reports, most recently updated in July
2010, and endorsed by the American Association for
the Study of Liver Diseases (AASLD) (Bruix &
Sherman, 2011). It consists of liver ultrasonography
every 6 months. Patients at risk for HCC need to be
entered into surveillance programs. There is Level
1 evidence for this and specific cut-offs of HCC incidence at which screening becomes cost effective
(Keefe, Lin, Keefe, Sanders & Owens, 2004). There is
concern that ultrasonography will miss tumors, particularly in the obese, advanced cirrhotic livers and
those with ascites. Computerized tomography or
magnetic resonance imaging is routinely utilized in
specialized clinics to screen at risk patients for HCC.
Our study likely underestimates the true incidence of HCC. It is our belief that many HCC cases
go underreported in cancer databases and cancer
registries. HCC is one of very few tumors that are
frequently diagnosed without tissue confirmation,
possibly making reporting the carcinomas difficult.
HCC can be diagnosed radiologically without need
for tissue confirmation, as long as findings on contrast enhanced CT scan or MRI are typical for HCC
(Former et al., 2008). Diagnosis guidelines by imaging are elaborated in the HCC Guidelines (Bruix &
Sherman, 2011). We want to strongly emphasize
that radiologic guidelines for HCC are to be applied
only to patients with cirrhosis and risk factors for
liver cancer, and not in any other circumstance. It
should also be understood that biopsy confirmation
of HCC presents several challenges. Not only it can
be risky in patients with cirrhosis and portal hypertension, but it can be also difficult to interpret, which
can result in delay of diagnosis and treatment, and
may also result in stage migration. At liver cancer
programs and transplant centers such as ours, HCC
is frequently diagnosed, treated with locoregional
therapy, resection, liver transplantation and systemic therapy, without tissue confirmation. Another
limitation of the study was the lack of important
variables, including the etiologies of liver disease,
treatments and survival. The creation of multidisciplinary liver cancer programs in the state of Florida,
particularly at most of the 6 liver transplant centers,
should be improving the overall survival of HCC.
This study is a preamble to upcoming prospective studies on HCC. The diagnosis of HCC should
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no longer be a death sentence. It should be recognized by all those treating patients at risk for HCC,
that the disease can be prevented (vaccination of
Hepatitis B, treatment of hepatitis B and C), that
careful screening can detect early disease, and that
treatments are available for early, intermediate and
advanced stages of the disease. Cure can be achieved
with locoregional therapy and resection, long term
disease free survival can be achieved with liver
transplantation, and improved survival can now be
achieved with transarterial chemoembolization and
systemic therapy (Llovet et al., 2008).
Healthy People 2020, the nation’s new 10-year
goals for health promotion and disease prevention,
have cancer objectives that support monitoring
trends in cancer incidence, mortality, and survival.
The recommendations for screening come from the
U.S. Preventive Services Task Force (United States
Preventative Task Force [USPSTF]). The Agency
for Healthcare Research and Quality’s Prevention
and Care Management Portfolio administers the
USPSTF (United States Department and Health and
Human Services: The Agency for Health Care Research and Quality [HHSTAFHCRAQ]). Surprisingly, the U.S. Preventive Services Task Force does
not have screening recommendations for liver cancer.
Conclusions
The incidence of hepatocellular carcinoma in
Florida in this study was three times higher than
previous reports from 2 decades ago (DOHBOE,
2005). This is the most updated study reporting the
incidence of HCC in Florida. The study utilized data
that, on average, was 5 years old. It is not an ethnic
and racial composition report. We expect the incidence of this cancer to continue to increase over the
next decade. HCC remains the fastest growing cancer in the U.S. In our next study, we would like to
report socioeconomic variables and perform group
and county studies of HCC.
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